[New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19].

Published in: Terapevticheskii arkhiv (2022)

Obtained results have shown high efficacy and statistically significant superiority of Aterixen over placebo. Thus, it allows us to consider it as viable medication for COVID-19 pathogenetic therapy.

Keyphrases

coronavirus disease
sars cov
anti inflammatory
healthcare
early onset
stem cells
emergency department
respiratory syndrome coronavirus
cell therapy
adverse drug
phase iii
study protocol